The upstart revolution in biotech

In the lead-up to BIO's annual meeting in Boston next week (see below), I've been lining up one-on-ones with some of the industry's emerging companies as I finalize our fifth annual Fierce 15. It struck me that this year there's a distinct abundance of promising companies being bankrolled by some very eager venture capital groups. It's a thoroughly non-scientific approach to trend-spotting, but for me it underscores just how strong the drug development field is right now. A good business plan, experienced management and a couple of intelligent licensing deals can propel a company into clinical development in relatively short order. These biotech upstarts may just find a shortcut around the old, lengthy timelines on human drug development. - John Carroll

Suggested Articles

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.  

Blocking tau appears to be just as fruitless as clearing amyloid buildup when it comes to helping Alzheimer’s disease patients.